enGene Therapeutics Inc ENGN
$1.78 $0.01 (0.57%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
ENGN Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, enGene Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
enGene Therapeutics Inc. Stock Analysis ENGN
United States Health Care Micro Cap enGene Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. The company is headquartered in Saint-Laurent, Quebec and currently employs 45 full-time employees. The company went IPO on 2021-12-10. The Company’s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II trial, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a range of sizes and types of cargo, including Deoxyribonucleic acid (DNA) and various forms of Ribonucleic acid (RNA).
enGene Therapeutics Inc (ENGN) Chart
Financial Metrics & Statements of enGene Therapeutics Inc (ENGN)
FAQ's for enGene Therapeutics Inc (ENGN)
- As of August 2026, enGene Therapeutics Inc ENGN is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes enGene Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in enGene Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of enGene Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of enGene Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of enGene Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for enGene Therapeutics Inc (ENGN)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
